Huntington Ingalls Industries Inc vs Revvity Inc — how do they compare? Huntington Ingalls Industries Inc trades at $277.03 (market cap $10.59B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays the higher dividend (2.05%). Which is the better fit depends on your goals.
| HII | RVTY | |
|---|---|---|
Market Cap | $10.59B | $12.33B |
Sector | Technology | Technology |
52-Week High | $453.73 | $117.75 |
52-Week Low | $253.96 | $82.26 |
Enterprise Value | $13.31B | $14.82B |
Dividend Yield | 2.05% | 0.25% |
Signals from Pluang's Aura AI — not financial advice
HII trades at $270.04, up 0.34% with a bearish technical signal despite recent earnings beats. The company maintains stable revenue around $12.5B with 4.71% net margins and attractive valuation metrics including P/E of 17.55 and P/S of 0.83. Recent developments include key shipbuilding milestones and unmanned vehicle contract awards, while analyst consensus shows 44% buy ratings with a $354.50 price target.
HII presents a mixed outlook with strong fundamentals and analyst optimism offset by bearish technical indicators. The stock offers value with below-market valuation multiples and consistent government contract flow, but faces execution risks in defense spending cycles and competitive pressures. Near-term catalyst includes Q2 2026 earnings on July 30, with current price representing 24% discount to consensus target.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →